Navigation Links
Drug Lessens Heart Attack Injury
Date:10/26/2007

Patients given ANP also had better long-term outcomes, researchers say

THURSDAY, Oct. 25 (HealthDay News) -- A type of drug called human atrial natriuretic peptide (ANP) can lessen cardiac injuries after heart attack and boost patient outcomes, a new study finds.

According to a Japanese study in this week's issue of The Lancet, use of the drug reduced the extent of damaged heart muscle (infarct) and lessened what's known as "reperfusion injuries," caused when blood rushes back to the heart.

The Japanese study included 277 acute heart attack patients who received intravenous ANP for three days and 292 patients who received the same dose of a placebo.

After a median follow-up of 2.7 years, infarct size was 15 percent less and left-ventricular ejection fraction (LVEF) was 5 percent higher in patients who received ANP, compared to those who were given the placebo.

LVEF is a measurement of the heart's pumping ability.

"We need to do another large-scale clinical trial to target clinical outcomes such as cardiovascular death, because our primary aim here was to test the reduction of infarct size," researchers at the National Cardiovascular Centre Suita, in Osaka, said in a statement.

"Our finding that treatment with ANP in the acute phase reduced the incidence or readmission to hospital for chronic heart failure could help to reduce the physical, medical, and economic burdens on people around the world," they concluded.

More information

The American Heart Association has more about heart attack treatments.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 26, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Airbags lessens oppressive eye injuries
2. Red Wine Lessens the Risk of Prostate Cancer
3. Adding Folic Acid to Flour Lessens Congenital Malformations
4. One in Three Heart Attack Patients Have No Chest Pains
5. Epileptic Seizures Can Be Duec to Heart Problem
6. Bypass Heart Surgery Performed Without General Anesthesia
7. New CPR Guidelines issued by Heart Association
8. White Cells Count Can Predict Heart Attack Death Risk
9. Vitamins-The answer to Heart Disease?
10. Fight Heart disease and Pain with Meditation
11. Heart disease in the newborn is related to maternal malnutrition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... METTLER TOLEDO has ... personnel have a basic understanding of the techniques they use so they can ... help them reduce waste and rework to create a leaner overall lab experience. ...
(Date:2/9/2016)... ... ... i2i Systems, an early innovator and developer of population health management technology, ... report, Population Health Management 2015: How Far Can Your Vendor Take You? , ... The latest KLAS Report, leveraging over 200 user interviews, shines a light on ...
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... L top-load case packer for pouches, bags, and flow wrapped products at WestPack ... co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case packing ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: